

Journal of Pharmaceutical Advanced Research

(An International Multidisciplinary Peer Review Open Access monthly Journal)

Available online at: www.jparonline.com

Alternative Measures for Irritable bowel syndrome Management

Abdul Kader Mohiuddin

Dr. M. Nasirullah Memorial Trust, Tejgaon, Dhaka, Bangladesh.

Received: 02.10.2019

Revised: 12.10.2019

Accepted: 16.10.2019

Published: 31.10.2019

ABSTRACT: About 30 to 40 % of adults claim to have frequent indigestion, and over 50 million visits are made annually to ambulatory care facilities for symptoms related to the digestive system. Irritable bowel syndrome (IBS) is present in patients with symptoms of chronic abdominal pain and altered bowel habits but no identifiable organic etiology. IBS has a prevalence of 1 to 20 % worldwide, although up to 75 % affected individuals never seek care. Diagnosing IBS can be challenging due to the nonspecific nature of symptoms, overlapping upper and lower abdominal symptoms, and the frequent presence of somatic and psychological comorbidities. Up to 80 % of IBS patients identify food as possible trigger for their symptoms, so they increasingly ask for dietary and behavioral counseling. Moderate-severe IBS is estimated to account for around 60 % of all IBS cases and has been shown to impose a considerable burden on patients. It is estimated that IBS-C accounts for around 30 % of IBS cases. The economic burden of IBS in the US is estimated at \$28 billion annually; a portion of these costs may be related to unnecessary and high-frequency tests, although few studies have assessed the factors underlying frequent tests and procedures among patients with IBS. About 32 % of IBS-C patients suffer depression as their condition almost every day in the previous month. Sexual dysfunction is positively associated with perceived GI symptom severity and HRQoL.

Corresponding author*

Dr. Abdul Kader Mohiuddin,
Secretary and Treasurer,
Dr. M. Nasirullah Memorial Trust,
Tejgaon, Dhaka, Bangladesh.
Tel: +8802-9110553
Mail ID: trymohi@gmail.com

Keywords: Irritable Bowel Syndrome, Low-FODMAP, Cognitive behavioral therapy, Complementary and Alternative Medicine, Chinese Herbal Medicine, brain-gut axis.

DISCUSSION:

Due to disappointing results with conventional IBS treatments, complementary and alternative medicines (CAM) are becoming attractive options for many patients [3,4]. Up to 50 % of patients declared that they used some form of CAM for their GI symptoms, ranging from biologically active compounds to mind-body interventions [5,6]. CAM alone and in conjunction with pharmacological treatments as an integrative approach to manage patients with IBS and improve their QoL [7]. Prokinetics are not specific to IBS and increase gastrointestinal motility in general by acting via

dopamine and 5-HT₃ receptors as antagonists or 5-HT₄ receptors as agonists [8]. Along with prokinetics, treatment revolves around the use of therapies which are not specifically approved/not truly effective for treating IBS-C, such as laxatives, antispasmodics, gastric relaxants, or central neuromodulators and bulking agents (e.g. dietary fibers) [9,10]. Novartis has agreed to continue to supply Zelnorm® (Tegaserod maleate) for use in emergency situations, due to an increased cardiovascular risk [9]. Alosetron hydrochloride (Lotronex), voluntarily withdrawn in November 2000 by GlaxoSmithKline, but put back on the market, is the only medication approved for the treatment of severe IBS-D in women who have inadequately responded to conventional therapy [10]. However, no studies have evaluated the efficacy of alosetron using the new Food Drug Administration (FDA) composite endpoint which requires improvement in both abdominal pain and diarrhea [11,12]. A mixture of dried powdered slippery elm bark, lactulose, oat bran, and licorice root significantly improved both bowel habit and IBS symptoms in patients with IBS-C [13]. More than 95 % of patients rated artichoke leaf extract as better than or at least equal to previous therapies administered for their symptoms, and the tolerability was very good [14]. Probiotics may be useful in the management of IBS, however, dose and specific bacterial strain are important [15]. Enteric-coated peppermint oil is a safe and effective therapy for the relief of abdominal pain and global symptoms and in adults with IBS. Menthacarin, the primary component blocks Ca²⁺ channels and causing the relaxation of intestinal smooth muscle tissue [15-17]. Iberogast (STW 5) is a liquid formulation of nine herbs (*Iberis amara totalisrecens*, *Angelicae radix*, *Cardui mariae fructus*, *Chelidonii herba*, *Liquiritiae radix*, *Matricariae flos*, *Melissae folium*, *Carvi fructus* and *Menthae piperitae folium*) used in clinical practice in Germany for more than 50 years, acts beneficially on abdominal symptom clusters as well as on individual GI symptoms in adults and children with efficacy, tolerability, reduced children school absenteeism [16-18]. Turmeric (*Curcuma longa*) or Java ginger (*Curcuma xanthorrhiza*) or curcumin, a biologically active phytochemical or combination with fennel oil was found to be beneficial, improved patient quality of life (QoL) (due to myorelaxant effect towards the intestinal muscle, involves not

only the cholinergic receptors, but also L type Calcium channels) but not statistically significant in IBS symptoms (compared with placebo) [19]. Enzymes comprise the endocannabinoid system in intestinal pain and motility in IBS is also claimed but no significant difference found with dronabinol/nabilone (synthetic compounds containing cannabinoids found in the marijuana plant) [20]. *Aloe vera* found to be improved QoL with insignificant/no severity symptom reduction in several studies and studies show its carcinogenic potential in the colon, nephrotoxicity and hepatotoxicity which surely demands very limited use unless necessary [18-22]. *Zingier officinale* also showed limited potential in symptom management [23]. Mixture of *Boswellia carterii*, *Zingiber officinale*, and *Achillea millefolium* improved QoL in men but not in women [24]. Although, an earlier study with *Mentha longifolia*, *Cyperus rotundus* and *Zingiber officinale* combination showed significant improvements after 8-weeks of treatment [25]. CAM for IBS include hypnosis, acupuncture, cognitive behavior therapy, yoga, probiotics, meditation, and herbal medicine [23-26]. The studies reported efficiency and safety of acupuncture alone or combined with Moxibustion or other Chinese herbal medicine (CHM) in IBS [27]. Like *Zingier officinale* and *Curcuma longa*, *Fumaria officinalis*, *Hypericum perforatum*, *Plantago psyllium* and Carmint (*Mentha spicata*, *Melissa officinalis*, *Coriandrum sativum*) do not have significant efficacy or at least similar efficacy as placebo is also reported [28]. CHM like Sishen Wan, Ma Zi Ren Wan, CCH1 (patented, modified herb formula), Hemp seed pill, JianpiTiaoganWenshen Recipe (JTWR), Chinese Medicine syndrome-differentiation therapy, Yunchang capsule, plantain-senna granule (CPSG), TongxieYaofang (TXYF) Granule, Changjishu soft elastic capsule, Tongyouqing and many more showed potentials in IBS [29]. The emerging role of brain-gut therapies in IBS is visible. Cognitive behavioral therapy (CBT) and gut-directed hypnosis are the primary behavioral interventions that are introduced to patients with gastrointestinal conditions [30]. IBS involves dysregulation of the brain-gut axis and psychological processes play an important role in the development and maintenance of the disorder [31]. Gut-focused hypnotherapy was found to be effective in primary and secondary care, but only small changes were found in intestinal micro biota composition [32]. Interceptive Exposure-




Fig 1. Image of Irritable Bowel Syndrome.

In particular, IBS is a disease representative of FGIDs in which abdominal pain and discomfort associated with abnormal bowel movements chronically persist and recur. These symptoms are known to be related to lifestyle habits, such as meals and stress. It has been reported that 50 to 90 % of patients have or had at some point one or more common psychiatric condition, including major depressive disorder, generalized anxiety disorder, social phobia, somatization disorder, or posttraumatic stress disorder. A survey by the Gastrointestinal Society in Canada showed that nearly 50 % had missed work or school due to IBS symptoms. In the US, Canada, and Israel, IBS symptoms are 1.5 to 2 times more prevalent among women than men. Moreover, women are more likely to report abdominal pain and constipation whereas men are more likely to report diarrhea ^[1,2].

based CBT program (CBT-IE) for IBS includes exposure to abdominal sensations in addition to psychoeducation, self-monitoring, cognitive restructuring, attention training, and in vivo exposure, which are often used in traditional CBT ^[33]. Home-based version of CBT produced significant and sustained gastrointestinal symptom improvement for patients with IBS compared with education ^[34]. Both web/phone-delivered CBT and home/clinic-based CBT was found to be effective than usual treatment in refractory IBS, resulted in substantial and enduring relief of multiple symptoms ^[36]. Although significant for both outcomes, the statistical analysis revealed CBT interventions have a greater effect on alleviating IBS symptoms severity rather than on reducing psychological distress ^[37]. Emotional stress exacerbates IBS symptoms, and mind-body interventions may be beneficial. Exercise (Yoga, walking/ aerobic physical activity, Tai Ji, mountaineering, and Baduanjin qigong activity) is potentially a feasible and effective treatment for IBS patients ^[38]. Yoga improved sleep, increased visceral sensitivity and reduced abdominal pain in

teens, adolescents and young adults, women and postmenopausal women ^[39]. Patients with irritable bowel syndrome might benefit from yoga and a low Fermentable Oligo-, Di-, Mono-saccharides and Polyols (FODMAP) diet, as both groups showed a reduction in gastrointestinal symptoms ^[40]. Low-FODMAPs, ketogenic gluten-free diets are considered therapeutic ^[41]. However, there are gaps in implementation of the low FODMAP diet in clinical practice, as well as long-term safety and efficacy ^[42]. A low FODMAP diet is only recommended as a second line treatment guided by qualified clinicians with specialized training ^[43]. Dietary sources fibers include oats, psyllium, ispaghula, nuts and seeds, some fruit and vegetables and pectins. An increase in fiber has often been suggested as an initial treatment for IBS ^[44]. There is strong evidence to support three mechanisms of action that are augmentation of small intestinal water, increased colonic fermentation and immune modulation ^[45]. However, water-insoluble fiber does not improve IBS symptoms, consuming soluble fiber improves overall IBS symptoms ^[46].

CONCLUSION:

There is tremendous alternative opportunity are there for treatment of Irritable Bowel Syndrome. The treatment of IBS by herbal medicine is significant one as they are more compatible and adaptable to biological system with least side effects. More extensive research has to be done to find out the chemical entity present in herbal medicines which are responsible for curing IBS.

ACKNOWLEDGEMENT:

I'm thankful to Dr. Elshazaly Saeed F.E.H. Elhassan, King Saud University, Saudi Arabia for his precious time to review my literature and for her thoughtful suggestions. I'm also grateful to seminar library of Faculty of Pharmacy, University of Dhaka and BANSDOC Library, Bangladesh for providing me books, journal and newsletters.

REFERENCES:

1. Abdul Rani R, Raja Ali RA, Lee YY. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. *Intest Res*, 2016; 14(4): 297-304.
2. Rahimi R, Abdollahi M. Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. *World J Gastroenterol*, 2012; 18(7): 589-600.
3. Wu JC. Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths? *Gastroenterol Hepatol*, 2010; 6(11): 705-711.
4. Adeyemo MA, Chang L. New treatments for irritable bowel syndrome in women. *Womens Health*, 2008; 4(6): 605-622.
5. Anastasi JK, Capili B, Chang M. Managing irritable bowel syndrome. *Am J Nurs*, 2013; 113(7): 42-52.
6. Nguyen L. Complementary and Alternative Medicine for the Management of Irritable Bowel Syndrome. *Gastroenterol Hepatol*, 2018; 14(9): 536-538.
7. Shen YH, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. *Can Fam Physician*, 2009; 55(2): 143-148.
8. Chiarioni G, Pesce M, Fantin A, Sarnelli G. Complementary and alternative treatment in functional dyspepsia. *United Eur Gastroenterol J*, 2018; 6(1): 5-12.
9. Goldenberg JZ, Steel A, Day A, Yap C, Bradley R, Cooley K. Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics. *Integr Med Res*, 2018; 7(3): 279-286.
10. Brien SB, Bishop FL, Riggs K, Stevenson D, Freire V, Lewith G. Integrated medicine in the management of chronic illness: a qualitative study. *Br J Gen Pract*, 2011; 61(583): e89-96.
11. Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: an integrative view. *World J Gastroenterol*, 2014; 20(2): 346-362.
12. Hussain Z, Quigley EM. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. *Aliment Pharmacol Ther*, 2006; 23(4): 465-471.
13. Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. *World J Gastroenterol*, 2014; 20(27): 8898-8909.
14. Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, *et al.* New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. *World J Gastroenterol*, 2017; 23(36): 6593-6627.
15. Sweetser S, Busciglio IA, Camilleri M, Bharucha AE, Szarka LA, Papathanasopoulos A, *et al.* Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. *Am J Physiol Gastrointest Liver Physiol*, 2009; 296(2): G295-301.
16. Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M, *et al.* Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. *United Eur Gastroenterol J*, 2017; 5(6): 773-788.
17. Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. *World J Gastroenterol*, 2014; 20(27): 8807-8820
18. Wang XJ, Camilleri M. Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. *World J Gastroenterol*, 2019; 25(10): 1185-1196.
19. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. *Br J Clin Pharmacol*, 2003; 56(4): 362-369.

20. Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. *Clin Colon Rectal Surg*, 2012; 25(1): 46-52.
21. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. *World J Gastroenterol*, 2014; 20(20): 6031-6043.
22. Reina J, Smith JW. Medical treatment of irritable bowel syndrome. *Clin Colon Rectal Surg*, 2005; 18(2): 102-108.
23. Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. *World J Gastroenterol*, 2008; 14(17): 2639-2649.
24. Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? *BMJ*, 2002; 325(7364): 592-595.
25. Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. *Therap Adv Gastroenterol*, 2010; 3(3): 165-172.
26. Hawrelak JA, Myers SP. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study. *J Altern Complement Med*, 2010; 16(10): 1065-1071.
27. Bahrami HR, Hamed S, Salari R, Noras M. Herbal Medicines for the Management of Irritable Bowel Syndrome: A Systematic Review. *Electron Physician*, 2016; 8(8): 2719-2725.
28. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *J Clin Gastroenterol*, 2014; 48(6): 505-512.
29. Grigoleit HG, Grigoleit P. Peppermint oil in irritable bowel syndrome. *Phytomedicine*, 2005; 12(8): 601-606.
30. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. *Dig Dis Sci*, 2010; 55(5): 1385-1390.
31. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. *Dig Liver Dis*, 2007; 39(6): 530-536.
32. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. *World J Gastroenterol*, 2014; 20(27): 8796-8806.
33. Chumpitazi BP, Kearns GL, Shulman RJ. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. *Aliment Pharmacol Ther*, 2018; 47(6): 738-752.
34. Lapina TL, Trukhmanov AS. Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice. *Dig Dis*, 2017; 35(1): 30-35.
35. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. *J Altern Complement Med*, 2004; 10(6): 1015-1018.
36. Khan I, Samson SE, Grover AK. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. *Med Princ Pract*, 2017; 26(3): 201-217.
37. Lakhani SE, Ford CT, Tepper D. *Zingiberaceae* extracts for pain: a systematic review and meta-analysis. *Nutr J*, 2015; 14: 50-55.
38. Bokic T, Storr M, Schicho R. Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. *Pharmacol*, 2015; 96(1-2): 76-85.
39. Hong SW, Chun J, Park S, Lee HJ, Im JP, Kim JS. *Aloe vera* is effective and safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. *J Neurogastroenterol Motil*, 2018; 24(4): 528-535.
40. Eswaran S, Dolan RD, Ball SC, Jackson K, Chey W. The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea. *J Acad Nutr Diet*, 2019; 18: S2212-2672.
41. Patel N, Lacy B. Does Yoga Help Patients With Irritable Bowel Syndrome? *Clin Gastroenterol Hepatol*, 2016; 14: 1732-1734.
42. Evans S, Lung KC, Seidman LC, Sternlieb B, Zeltzer LK, Tsao JC. Iyengar yoga for adolescents and young adults with irritable bowel syndrome. *J Pediatr Gastroenterol Nutr*, 2014; 59(2): 244-253.
43. Radu M, Moldovan R, Pintea S, Băban A, Dumitrascu D. Predictors of outcome in cognitive and behavioural interventions for irritable bowel syndrome. A meta-analysis. *J Gastrointest Liver Dis*, 2018; 27(3): 257-263.

44. Riehl ME. The Emerging Role of Brain-Gut Therapies for Irritable Bowel Syndrome. *Gastroenterol Hepatol*, 2018; 14(7): 436-438.
45. Forbes A, Jackson S, Walter C, Quraishi S, Jacyna M, Pitcher M. Acupuncture for irritable bowel syndrome: a blinded placebo-controlled trial. *World J Gastroenterol*, 2005; 1(26): 4040-4044.
46. Lin X, Liu X, Xu J, Cheng KK, Cao J, Liu T, *et al.* Metabolomics analysis of herb-partitioned moxibustion treatment on rats with diarrhea-predominant irritable bowel syndrome. *Chin Med*, 2019; 14: 18-24.

Conflict of Interest: None

Source of Funding: Nil

Paper Citation: Mohiuddin AK. Alternative Measures for Irritable bowel syndrome Management. *J Pharm Adv Res*, 2019; 2(10): 657-662.